Tempest Therapeutics directors Brady, Raab, Pellizzari resign from board
Tempest Therapeutics, Inc. TPST | 0.00 |
- Tempest Therapeutics disclosed board resignations by Stephen Brady, Michael Raab, and Christine Pellizzari, effective May 22, 2026.
- The departures were not tied to any disputes over the company’s operations, policies, or practices.
- Separation agreements provide for a waiver of accrued and unpaid director retainer fees, while leaving existing stock option rights and share ownership unchanged.
- Indemnification arrangements remain in effect, with underlying protections continuing for six years from separation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-237150), on May 22, 2026, and is solely responsible for the information contained therein.
